Cliniques Universitaires Saint-Luc
Head of the department of Clinical Chemistry, Prof Gruson's group is laboratory testing in all the fields of clinical chemistry. It also tests for cardiac biomakers of early risk estimation, diagnosis of acute myocardial infarction and diagnosis and prognosis of heart failure.
- Identification, evaluation and implementation of biomarkers testing
- Multidisciplinary team discussion for the use of cardiac biomarkers
- Chemistry assays, immunoassays, mass spectrometry, heart failure, myocardial infartcion, diabetes, ISO, digital health
Interested in collaborating on
Cardiac biomarkers, proteomic, omics, machine learning.
Selected publications on lncRNA
Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction
Gruson D, Ferracin B, Ahn SA, Rousseau MF. Int J Cardiol. 2017, 248:270-273.
Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients
Gruson D, Ferracin B, Ahn SA, Rousseau MF. Int J Cardiol. 2015, 189:185-7.
PTH: Potential role in management of heart failure
Gruson D, Buglioni A, Burnett JC Jr. PTH: Potential role in management of heart failure. Clin Chim Acta. 2014, 433:290-6.
Testing for Soluble ST2 in Heart Failure Patients: Reliability of a Point of Care Method
Gruson D, Ferracin B, Ahn SA, Rousseau MF. Clin Lab. 2017, 63(1):141-145.
Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?
Gruson D, Ko G. Clin Biochem. 2012, 45(10-11):719-26.